On July 30, 2023, Baudax Bio, Inc. entered into Amendment No. 1 to Forbearance Agreement and Amendment No. 6 to Credit Agreement (the Amendment?, by and among Baudax Bio, Inc., Baudax Bio N.A. LLC, Baudax Bio Limited and TeraImmune, LLC, the lenders party thereto (the Lenders) and Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent for the Lenders, which modifies (i) that certain Credit Agreement, dated as of May 29, 2020 (as amended from time to time, the Credit Agreement) and (ii) that certain Forbearance Agreement, dated as of June 29, 2023.

Pursuant to the Amendment, the Lenders agreed to, among other things, forbear from exercising their rights and remedies with respect to certain events of default under the Credit Agreement until October 31, 2023 and modify certain provision of the Credit Agreement as set forth therein.